Inaba T, Shimazaki C, Tatsumi T, Yamagata N, Hirata T, Goto H, Fujita N, Nakagawa M, Fujita N, Miyazaki S
Second Dept. of Medicine, Kyoto Prefectural University of Medicine.
Gan To Kagaku Ryoho. 1994 Mar;21(4):535-8.
A 77-year-old female with left hemiplegia caused by cerebral infarction and with mild senile dementia was admitted for further examination of hematological abnormalities. She was diagnosed as acute myelogenous leukemia (AML-M5a) according to French-American-British classification. Since intensive combination chemotherapy seemed difficult, she was treated with oral administration of cytarabine ocfosfate (200 mg/day, for 14 days), a cytidine deaminase-resistant derivative of Ara-C, resulting in complete remission. Major side effects were nausea, vomiting and appetite loss, but their incidences were reduced tolerably when cytarabine ocfosfate was given just before sleeping. Cytarabine ocfosfate might be useful to treat AML in elderly patients having certain complications such as cerebrovascular disease.
一名77岁女性因脑梗死导致左侧偏瘫且患有轻度老年痴呆症,入院进一步检查血液学异常。根据法美英分类标准,她被诊断为急性髓系白血病(AML-M5a)。由于强化联合化疗似乎难以实施,她接受了口服磷酰阿糖胞苷(200毫克/天,共14天)治疗,磷酰阿糖胞苷是阿糖胞苷的一种抗胞苷脱氨酶衍生物,治疗后获得完全缓解。主要副作用为恶心、呕吐和食欲减退,但在睡前服用磷酰阿糖胞苷时,这些副作用的发生率可得到 tolerably 降低。磷酰阿糖胞苷可能对治疗患有某些并发症(如脑血管疾病)的老年AML患者有用。 (注:原文中“tolerably”翻译时保留英文,因未找到合适中文对应词准确表达其在文中含义)